Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
OpenResearch announcementOpportunity PAR-28-056

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

National Institutes of Health · Department of Health and Human Services

At a glance

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) is an open federal cooperative agreement opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due November 5, 2029. Individual awards are listed as up to $600K. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.393 (Cancer Cause and Prevention Research).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

  1. Sep 25, 2026Posted
  2. Nov 5, 2029Application deadlinenext date
  3. Dec 1, 2026 (est.)Est. award date
  4. Jan 4, 2030Archived
Posted
Sep 25, 2026
Close date
Nov 5, 2029
Archive date
Jan 4, 2030
Est. award date
Dec 1, 2026
Award floor
Not specified
Award ceiling
$600,000
Est. total funding
Not specified
Expected awards
Not specified
Cost sharing
Not required
Funding instrument
Cooperative Agreement
Opportunity category
Discretionary

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public colleges & universities
  • Federally recognized tribal governments
  • Public & Indian housing authorities
  • Native American tribal organizations
  • 501(c)(3) nonprofits
  • Nonprofits without 501(c)(3) status
  • Private colleges & universities
  • For-profit organizations (not small businesses)
  • Small businesses
  • Others (see notice)

Additional information on eligibility (from the notice)

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium.

Full announcement & documents

The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.

How to apply

0 of 8 done · progress saved in this browser

Assistance Listing

What is an ALN?

Reported obligations under ALN 93.393

Historical data · not a prediction
FY24$755M
FY25$835M
FY26$520M est.
Source: SAM.gov Assistance Listing 93.393. Program-wide totals, not awards from this specific opportunity.

Who was funded under ALN 93.393

Historical data · not a prediction

Since October 1, 2023, 3,097 grant awards had funding actions under Cancer Cause and Prevention Research, with 3,423 sub-awards passed on to other organizations. These are program-wide awards, not awards from this specific notice.

  1. THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER$87.6M
  2. DANA-FARBER CANCER INSTITUTE, INC.$68.4M
  3. SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH$57M
  4. THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK$52.3M
  5. UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL$49.4M
Recipients, states, recent awards and sub-awards →Source: USAspending.gov.

Agency contact (as published)

National Institutes of Health
ncipcdc@nih.gov
301-402-2541

Quick answers

When is the deadline for “Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)”?

According to the official notice, applications are due November 5, 2029. Confirm the deadline and submission time on Grants.gov before applying.

Who is eligible to apply for “Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)”?

The official notice names these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How much funding is available through “Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)”?

Per the notice, individual awards are listed as up to $600k.

How do I apply for “Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity PAR-28-056), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.